Mice with hepatocyte-specific deletion of Foxk1 exhibit reduced lipogenic activities and increased catabolic activities, which are associated with protection from hepatic steatosis, inflammation, and fibrosis in pre-clinical MASLD models [62]. Here, FOXK1 is linked to metabolic dysfunction-associated steatotic liver disease.